Nuwellis, Inc. (NUWE) - Q3 2025 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2025. Nuwellis, Inc. is a medical technology company focused on commercializing the Aquadex SmartFlow system for ultrafiltration therapy to treat fluid overload in patients unresponsive to diuretics. The company operates as a single segment and is headquartered in Eden Prairie, Minnesota.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Net Sales | $2.22 million | $2.37 million | $5.85 million | $6.42 million |
| Gross Profit | $1.45 million | $1.66 million | $3.47 million | $4.32 million |
| Gross Margin | 65.2% | 70.0% | 59.4% | 67.3% |
| Operating Loss | ($2.70 million) | ($1.53 million) | ($8.66 million) | ($8.60 million) |
| Net Income (Loss) | $0.47 million | $2.36 million | ($15.10 million) | ($9.70 million) |
| Cash and Equivalents | $3.09 million | $1.91 million (Q3 2024) | As of Sept 30, 2025 | |
| Accumulated Deficit | ($313.89 million) | As of Sept 30, 2025 |
Liquidity & Debt: The company reported no long-term debt. Total liabilities were $4.07 million, primarily consisting of accounts payable ($2.67 million) and warrant liabilities ($0.42 million). Cash flow from operations used $7.78 million for the nine months ended September 30, 2025.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 6.3% quarter-over-quarter and 8.9% year-over-year (YTD). The decline is attributed to lower console average selling prices, a decrease in international operations, and the absence of one-time prior-year revenue from SeaStar Medical.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses increased 31.0% in Q3 2025 compared to Q3 2024, driven by increased headcount and professional services. However, YTD SG&A decreased 2.3% due to cost-cutting measures in the first half of the year.
- Net Income Volatility: While the company reported a net income of $0.47 million for Q3 2025, this was largely driven by a $3.16 million gain from the change in fair value of warrant liabilities. On a YTD basis, the company reported a net loss of $15.10 million, significantly higher than the $9.70 million loss in the prior year, due to a $10.55 million financing expense related to the June 2025 offering.
- Capital Structure: The company executed a 1-for-42 reverse stock split in July 2025 to regain Nasdaq compliance. It also completed a public offering in June 2025 raising approximately $5.0 million and initiated an At-The-Market (ATM) offering in September 2025.
Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for at least twelve months from the filing date due to an accumulated deficit of $313.9 million and recurring operating losses. The company expects existing capital to support operations into the first quarter of 2026 but will need to raise additional capital.
- Strategic Shifts:
- International Exit: The company announced an exit from international operations to focus exclusively on the U.S. market, accruing approximately $254,000 in exit fees.
- Clinical Trial Termination: The REVERSE-HF clinical trial was terminated to save approximately $4.0 million over 2.5 years, allowing a focus on outpatient heart failure, pediatric, and critical care applications.
- Manufacturing: Production responsibilities for consoles, circuits, and catheters were transitioned to KDI Precision Manufacturing.
- Unusual Items: The Q3 net income was significantly impacted by non-cash gains from warrant liability revaluations. Conversely, the YTD net loss was inflated by a $10.55 million "Day 1 interest" financing expense from the June 2025 offering where warrant valuation exceeded gross proceeds.
- Risks: Risks include potential delisting from Nasdaq if equity requirements are not met, reliance on sole-source suppliers, and regulatory risks regarding off-label use of the Aquadex System.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $3.09 million cash balance against the projected burn rate to confirm the "first quarter of 2026" liquidity timeline.
- Warrant Liability: Monitor the fair value of remaining warrant liabilities (Series B) and the potential for further reclassifications or exercises that could impact equity and earnings.
- ATM Offering Progress: Track the utilization of the $4.65 million ATM facility and the pricing of shares sold to assess dilution and capital raising effectiveness.
- Revenue Concentration: Review customer concentration risks, noting that two customers represented 11% of net sales each in Q3 2025.
- Manufacturing Transition: Confirm the successful integration of KDI Precision Manufacturing and the impact on cost of goods sold and supply chain stability.